Plasma Cathepsin S and Cathepsin S/Cystatin C Ratios Are Potential Biomarkers for COPD

Takahiro Nakajima, Hidetoshi Nakamura, Caroline A. Owen, Shuichi Yoshida, Keishi Tsuduki, Shotaro Chubachi, Toru Shirahata, Shuko Mashimo, Miho Nakamura, Saeko Takahashi, Naoto Minematsu, Hiroki Tateno, Seitaro Fujishima, Koichiro Asano, Bartolome R. Celli, Tomoko Betsuyaku

研究成果: Article

9 引用 (Scopus)

抄録

Purpose. This study aimed to examine whether plasma levels of cathepsin S or its inhibitor, cystatin C, may serve as biomarkers for COPD. Patients and Methods. We measured anthropometrics and performed pulmonary function tests and chest CT scans on 94 patients with COPD and 31 subjects with productive cough but no airflow obstruction ("at risk"; AR). In these subjects and in 52 healthy nonsmokers (NS) and 66 healthy smokers (HS) we measured plasma concentrations of cathepsin S and cystatin C using an ELISA. Data were analyzed using simple and logistic regression and receiver operating characteristic analyses. Results. Cathepsin S and cystatin C plasma levels were significantly higher in the COPD and AR groups than in the NS and HS groups (p<0.01). Among the COPD patients and AR subjects, plasma cathepsin S levels and cathepsin S/cystatin C ratios, but not cystatin C levels, were negatively related to severe airflow limitation (% FEV1 predicted < 50%; p=0.005) and severe emphysema as assessed by low attenuation area (LAA) score on chest CT scans (LAA ≥ 8.0; p=0.001). Conclusion. Plasma cathepsin S and cathepsin S/cystatin C ratios may serve as potential biomarkers for COPD.

元の言語English
記事番号4093870
ジャーナルDisease Markers
2016
DOI
出版物ステータスPublished - 2016

Fingerprint

cathepsin S
Cystatin C
Biomarkers
Chronic Obstructive Pulmonary Disease
Plasmas
Cathepsin C
Computerized tomography
Thorax
Respiratory Function Tests
Emphysema
Cough
ROC Curve
Logistics

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Clinical Biochemistry
  • Biochemistry, medical

これを引用

Nakajima, T., Nakamura, H., Owen, C. A., Yoshida, S., Tsuduki, K., Chubachi, S., ... Betsuyaku, T. (2016). Plasma Cathepsin S and Cathepsin S/Cystatin C Ratios Are Potential Biomarkers for COPD. Disease Markers, 2016, [4093870]. https://doi.org/10.1155/2016/4093870

Plasma Cathepsin S and Cathepsin S/Cystatin C Ratios Are Potential Biomarkers for COPD. / Nakajima, Takahiro; Nakamura, Hidetoshi; Owen, Caroline A.; Yoshida, Shuichi; Tsuduki, Keishi; Chubachi, Shotaro; Shirahata, Toru; Mashimo, Shuko; Nakamura, Miho; Takahashi, Saeko; Minematsu, Naoto; Tateno, Hiroki; Fujishima, Seitaro; Asano, Koichiro; Celli, Bartolome R.; Betsuyaku, Tomoko.

:: Disease Markers, 巻 2016, 4093870, 2016.

研究成果: Article

Nakajima, T, Nakamura, H, Owen, CA, Yoshida, S, Tsuduki, K, Chubachi, S, Shirahata, T, Mashimo, S, Nakamura, M, Takahashi, S, Minematsu, N, Tateno, H, Fujishima, S, Asano, K, Celli, BR & Betsuyaku, T 2016, 'Plasma Cathepsin S and Cathepsin S/Cystatin C Ratios Are Potential Biomarkers for COPD', Disease Markers, 巻. 2016, 4093870. https://doi.org/10.1155/2016/4093870
Nakajima, Takahiro ; Nakamura, Hidetoshi ; Owen, Caroline A. ; Yoshida, Shuichi ; Tsuduki, Keishi ; Chubachi, Shotaro ; Shirahata, Toru ; Mashimo, Shuko ; Nakamura, Miho ; Takahashi, Saeko ; Minematsu, Naoto ; Tateno, Hiroki ; Fujishima, Seitaro ; Asano, Koichiro ; Celli, Bartolome R. ; Betsuyaku, Tomoko. / Plasma Cathepsin S and Cathepsin S/Cystatin C Ratios Are Potential Biomarkers for COPD. :: Disease Markers. 2016 ; 巻 2016.
@article{53353e1bf2ac41cea016bd9caa218128,
title = "Plasma Cathepsin S and Cathepsin S/Cystatin C Ratios Are Potential Biomarkers for COPD",
abstract = "Purpose. This study aimed to examine whether plasma levels of cathepsin S or its inhibitor, cystatin C, may serve as biomarkers for COPD. Patients and Methods. We measured anthropometrics and performed pulmonary function tests and chest CT scans on 94 patients with COPD and 31 subjects with productive cough but no airflow obstruction ({"}at risk{"}; AR). In these subjects and in 52 healthy nonsmokers (NS) and 66 healthy smokers (HS) we measured plasma concentrations of cathepsin S and cystatin C using an ELISA. Data were analyzed using simple and logistic regression and receiver operating characteristic analyses. Results. Cathepsin S and cystatin C plasma levels were significantly higher in the COPD and AR groups than in the NS and HS groups (p<0.01). Among the COPD patients and AR subjects, plasma cathepsin S levels and cathepsin S/cystatin C ratios, but not cystatin C levels, were negatively related to severe airflow limitation ({\%} FEV1 predicted < 50{\%}; p=0.005) and severe emphysema as assessed by low attenuation area (LAA) score on chest CT scans (LAA ≥ 8.0; p=0.001). Conclusion. Plasma cathepsin S and cathepsin S/cystatin C ratios may serve as potential biomarkers for COPD.",
author = "Takahiro Nakajima and Hidetoshi Nakamura and Owen, {Caroline A.} and Shuichi Yoshida and Keishi Tsuduki and Shotaro Chubachi and Toru Shirahata and Shuko Mashimo and Miho Nakamura and Saeko Takahashi and Naoto Minematsu and Hiroki Tateno and Seitaro Fujishima and Koichiro Asano and Celli, {Bartolome R.} and Tomoko Betsuyaku",
year = "2016",
doi = "10.1155/2016/4093870",
language = "English",
volume = "2016",
journal = "Disease Markers",
issn = "0278-0240",
publisher = "IOS Press",

}

TY - JOUR

T1 - Plasma Cathepsin S and Cathepsin S/Cystatin C Ratios Are Potential Biomarkers for COPD

AU - Nakajima, Takahiro

AU - Nakamura, Hidetoshi

AU - Owen, Caroline A.

AU - Yoshida, Shuichi

AU - Tsuduki, Keishi

AU - Chubachi, Shotaro

AU - Shirahata, Toru

AU - Mashimo, Shuko

AU - Nakamura, Miho

AU - Takahashi, Saeko

AU - Minematsu, Naoto

AU - Tateno, Hiroki

AU - Fujishima, Seitaro

AU - Asano, Koichiro

AU - Celli, Bartolome R.

AU - Betsuyaku, Tomoko

PY - 2016

Y1 - 2016

N2 - Purpose. This study aimed to examine whether plasma levels of cathepsin S or its inhibitor, cystatin C, may serve as biomarkers for COPD. Patients and Methods. We measured anthropometrics and performed pulmonary function tests and chest CT scans on 94 patients with COPD and 31 subjects with productive cough but no airflow obstruction ("at risk"; AR). In these subjects and in 52 healthy nonsmokers (NS) and 66 healthy smokers (HS) we measured plasma concentrations of cathepsin S and cystatin C using an ELISA. Data were analyzed using simple and logistic regression and receiver operating characteristic analyses. Results. Cathepsin S and cystatin C plasma levels were significantly higher in the COPD and AR groups than in the NS and HS groups (p<0.01). Among the COPD patients and AR subjects, plasma cathepsin S levels and cathepsin S/cystatin C ratios, but not cystatin C levels, were negatively related to severe airflow limitation (% FEV1 predicted < 50%; p=0.005) and severe emphysema as assessed by low attenuation area (LAA) score on chest CT scans (LAA ≥ 8.0; p=0.001). Conclusion. Plasma cathepsin S and cathepsin S/cystatin C ratios may serve as potential biomarkers for COPD.

AB - Purpose. This study aimed to examine whether plasma levels of cathepsin S or its inhibitor, cystatin C, may serve as biomarkers for COPD. Patients and Methods. We measured anthropometrics and performed pulmonary function tests and chest CT scans on 94 patients with COPD and 31 subjects with productive cough but no airflow obstruction ("at risk"; AR). In these subjects and in 52 healthy nonsmokers (NS) and 66 healthy smokers (HS) we measured plasma concentrations of cathepsin S and cystatin C using an ELISA. Data were analyzed using simple and logistic regression and receiver operating characteristic analyses. Results. Cathepsin S and cystatin C plasma levels were significantly higher in the COPD and AR groups than in the NS and HS groups (p<0.01). Among the COPD patients and AR subjects, plasma cathepsin S levels and cathepsin S/cystatin C ratios, but not cystatin C levels, were negatively related to severe airflow limitation (% FEV1 predicted < 50%; p=0.005) and severe emphysema as assessed by low attenuation area (LAA) score on chest CT scans (LAA ≥ 8.0; p=0.001). Conclusion. Plasma cathepsin S and cathepsin S/cystatin C ratios may serve as potential biomarkers for COPD.

UR - http://www.scopus.com/inward/record.url?scp=85004024951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85004024951&partnerID=8YFLogxK

U2 - 10.1155/2016/4093870

DO - 10.1155/2016/4093870

M3 - Article

C2 - 27994288

AN - SCOPUS:85004024951

VL - 2016

JO - Disease Markers

JF - Disease Markers

SN - 0278-0240

M1 - 4093870

ER -